Insider · CIK 0001586965
Mark J Enyedy
director
Files at BMRN (BIOMARIN PHARMACEUTICAL INC), CRL (CHARLES RIVER LABORATORIES INTERNATIONAL, INC.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 2, 2025 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | AGrant or award Common Stock | +946 | $135.04 | $128k | 946 | Jun 4, 2025 |
| Jun 2, 2025 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | AGrant or award Stock Options (Right to Buy)derivative | +2,082 | $135.04 | $281k | 2,082 | Jun 4, 2025 |
| May 20, 2025 | BMRN BIOMARIN PHARMACEUTICAL INC | AGrant or award Common Stock | +6,650 | $0.00 | $0 | 13,550 | May 22, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.